Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 8/20 | 0.84 |
| ▸ | CA1 known ✓ | P00915 | 6/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30685115 | 1.00 | CA2 (0.84) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL28366820 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL22772366 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL28957154 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL10944798 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL5057190 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| Potassium Ion SCHEMBL15821222 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| Lithium Ion SCHEMBL22772374 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| SCHEMBL22772375 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR | |
| Potassium Ion SCHEMBL28483811 | 0.96 | CA2 (0.77) | CA2CA1NFKB1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | claimed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | claimed |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2005-03-17 | — | — | US | claimed |
| EP-1532130-B1 | PROCESS FOR THE PRODUCTION OF AN IMMUNOSUPPRESSANT | BIOCON LTD (IN) | 2009-11-04 | — | — | EP | disclosed |
| US-7470786-B2 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2008-12-30 | — | — | US | disclosed |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | LUPIN LIMITED (RESEARCH PARK) (IN) | 2008-08-21 | — | — | US | disclosed |
| EP-1532130-A4 | PROCESS FOR THE PRODUCTION OF AN IMMUNOSUPPRESSANT | BIOCON LTD (IN) | 2008-03-19 | — | — | EP | disclosed |
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-03-01 | — | — | US | disclosed |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | LUPIN LIMITED (RESEARCH PARK) (IN) | 2007-01-18 | — | — | US | disclosed |
| EP-1532130-A1 | PROCESS FOR THE PRODUCTION OF AN IMMUNOSUPPRESSANT | Biocon Limited (IN) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | DATTA DEBASHISH (IN) | 2005-03-17 | — | — | US | disclosed |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | LUPIN LIMITED (IN) | 2005-03-17 | — | — | US | disclosed |
| WO-2004020426-A1 | PROCESS FOR THE PRODUCTION OF AN IMMUNOSUPPRESSANT | BIOCON LIMITED (IN) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049749-A1 | Method for Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885NFKB1 3294/4885 |
| US-20050059820-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885NFKB1 3294/4885 |
| US-20070015917-A1 | Method For Manufacture of Ceftriaxone Sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885NFKB1 3294/4885 |
| US-20080200670-A1 | METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM | CHAT, TREH, MRPL21 | CA2 1034/4885CA1 1294/4885NFKB1 3343/4885 |
| US-20050059821-A1 | Method for manufacture of ceftriaxone sodium | TREH, CHAT, MRPL21 | CA2 1218/4885CA1 1613/4885NFKB1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.